Literature DB >> 8427051

Pseudohypoparathyroidism with osteitis fibrosa cystica: direct demonstration of skeletal responsiveness to parathyroid hormone in cells cultured from bone.

T M Murray1, L G Rao, M M Wong, J P Waddell, R McBroom, C S Tam, F Rosen, M A Levine.   

Abstract

A young girl had tibial osteotomies at age 14 for genu valgum and then had recurrent tibial cysts over a number of years. Hypocalcemia and hyperphosphatemia were first noted at age 21. The diagnosis of pseudohypoparathyroidism was made at age 28, when elevated plasma PTH was detected. Clinical and biochemical features, including a PTH response test and assay of RBC Gs, established the diagnosis of pseudohypoparathyroidism type 1b. Failure to suppress plasma PTH with vitamin D therapy led to an exacerbation of her cystic bone disease; there were widespread lytic lesions radiologically, most of which took up [99mTc]diphosphonate on bone scan. Microradioscopy revealed evidence of resorption of phalangeal tufts. Bone biopsy showed osteitis fibrosa cystica. During an orthopedic procedure, trabecular bone fragments were taken from her right humerus, and bone-derived cells cultured using an explant technique. The cultured cells were osteoblast-like in morphology, fully responsive to PTH, cholera toxin, forskolin, and PGE1 in vitro, and had an alkaline phosphatase and osteocalcin response to 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3]. Following this examination of skeletal responsiveness, attempts were made to suppress the elevated plasma PTH levels and symptomatic bone disease by optimizing therapy with oral 1,25-(OH)2D3. When bone pain associated with the cystic bone disease failed to resolve, the patient underwent total parathyroidectomy, following which the bone pain gradually resolved. This is the first direct demonstration of PTH responsiveness in cultured bone cells in the syndrome of pseudohypoparathyroidism with osteitis fibrosa cystica.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8427051     DOI: 10.1002/jbmr.5650080111

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  16 in total

Review 1.  Clinical spectrum and pathogenesis of pseudohypoparathyroidism.

Authors:  M A Levine
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

Review 2.  Genetics of endocrine and metabolic disorders: parathyroid.

Authors:  R V Thakker
Journal:  Rev Endocr Metab Disord       Date:  2004-03       Impact factor: 6.514

Review 3.  Pseudohypoparathyroidism and Gsα-cAMP-linked disorders: current view and open issues.

Authors:  Giovanna Mantovani; Anna Spada; Francesca Marta Elli
Journal:  Nat Rev Endocrinol       Date:  2016-04-22       Impact factor: 43.330

4.  Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B.

Authors:  Nicola M Neary; Diala El-Maouche; Rachel Hopkins; Steven K Libutti; Arnold M Moses; Lee S Weinstein
Journal:  J Clin Endocrinol Metab       Date:  2012-06-26       Impact factor: 5.958

5.  Bone mineral density in pseudohypoparathyroidism type 1a.

Authors:  Dominique N Long; Michael A Levine; Emily L Germain-Lee
Journal:  J Clin Endocrinol Metab       Date:  2010-07-07       Impact factor: 5.958

6.  A GNAS1 imprinting defect in pseudohypoparathyroidism type IB.

Authors:  J Liu; D Litman; M J Rosenberg; S Yu; L G Biesecker; L S Weinstein
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

7.  Age-dependent expression of osteoblastic phenotypic markers in normal human osteoblasts cultured long-term in the presence of dexamethasone.

Authors:  M S Sutherland; L G Rao; S A Muzaffar; J N Wylie; M M Wong; R J McBroom; T M Murray
Journal:  Osteoporos Int       Date:  1995       Impact factor: 4.507

8.  Osteosclerosis in two brothers with autosomal dominant pseudohypoparathyroidism type 1b: bone histomorphometric analysis.

Authors:  Anne Marie Sbrocchi; Frank Rauch; Margaret L Lawson; Stasia Hadjiyannakis; Sarah Lawrence; Murat Bastepe; Harald Jüppner; Leanne Marie Ward
Journal:  Eur J Endocrinol       Date:  2010-11-09       Impact factor: 6.664

9.  Developmental upregulation of human parathyroid hormone (PTH)/PTH-related peptide receptor gene expression from conserved and human-specific promoters.

Authors:  J D Bettoun; M Minagawa; G N Hendy; L C Alpert; C G Goodyer; D Goltzman; J H White
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

10.  In vitro study of osteoblastic cells from patients with idiopathic osteoporosis and comparison with cells from non-osteoporotic controls.

Authors:  M M Wong; L G Rao; H Ly; L Hamilton; S Ish-Shalom; W Sturtridge; J Tong; R McBroom; R G Josse; T M Murray
Journal:  Osteoporos Int       Date:  1994-01       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.